^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TGFβ targeting CAR-T cells

i
Other names: TGFβ targeting CAR-T cells
Associations
Company:
Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
Drug class:
TGFβ-targeted CAR-T immunotherapy
Associations
5ms
ZZCART-003: GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (clinicaltrials.gov)
P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2029 --> Aug 2036 | Trial primary completion date: Aug 2025 --> Aug 2029
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
GPC3 (Glypican 3)
|
TGFβ targeting CAR-T cells
over1year
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (clinicaltrials.gov)
P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2024 --> Aug 2029 | Trial primary completion date: Aug 2022 --> Aug 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
TGFβ targeting CAR-T cells